Edesa Biotech, Inc.

Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company exploring new ways to treat inflammatory and immune-related diseases, including new first-in-class alternatives to steroids.

Novel experimental treatments for immune and inflammatory diseases.

Image of Topical Cream Being Applied to Rash on Hand

Countering Dysfunctional Immune Responses

Our novel monoclonal antibodies suppress certain immune signaling proteins, including Toll-like Receptor 4 (TLR4), which is associated with a broad range of acute and chronic diseases.

Acute Respiratory Distress Syndrome

We have prioritized the study of our first-in-class monoclonal antibody in patients with Acute Respiratory Distress Syndrome. This life-threatening for of lung injury is the result of an overactive and dysfunctional innate immune response, sometimes described as a “cytokine storm.” Our product candidate is designed to inhibit this cytokine storm and the inflammation, fluid accumulation and lung injury it causes.

Inhibiting the Inflammation Cascade

We believe that our technology, called sPLA2 inhibitors,  will have a superior therapeutic effect because the inflammatory process will be inhibited at its inception rather than after inflammation has occurred.

Allergic Contact Dermatitis

Our lead product candidate, EB01, is a non-steroidal, anti-inflammatory treatment for chronic allergic contact dermatitis. In two clinical studies, this topical therapy has demonstrated significant improvement of multiple symptoms in contact dermatitis patients. Edesa also intends to expand the utility of our sPLA2 inhibitor technology across multiple indications.

Recipient of a Strategic Innovation Fund Grant Award

“We are investing $14 million to help Edesa Biotech… develop a treatment for COVID-19.

This treatment could save the lives of people who become seriously ill due to COVID-19.”

Canadian Prime Minister Justin Trudeau
Press Conference, February 2, 2021